

Figure S1. AXL overexpression and prognosis in mesothelioma patients. **A)** TCGA gene expression profiling data analysis for 87 mesotheliomas shows that *AXL* expression is higher in mesothelioma patient samples compared to most other tumor types. (T = tumor tissue; N = companion normal tissue) **B)** *AXL* expression in four histological mesothelioma subtypes from TCGA. **C)** Higher *AXL* expression levels in the mesothelioma TCGA series correlates with poorer survival in patients with biphasic ($p = 0.0023$) and epithelioid ($p = 0.0032$) mesothelioma.




Figure S2. Immunoblotting evaluation of the expression of AXL and p53 in mesothelioma total cell lysates. The left panel shows mesothelioma cell lines (1-10) and the right panel shows primary frozen tumors (1-8). Actin staining is a loading control. Expression quantitations of AXL, p53, and actin were normalized to MESO924 and sample 1, respectively. The whole blot (uncropped blots) show in the Figure S3.

Table S1. Primers of chromatin immunoprecipitation-PCR (ChiP-PCR).

Primer Name	Primer Sequence
<i>p53 promoter 1-F</i>	ATTCGGGGCAGAAAACGCTACATG
<i>p53 promoter 1-R</i>	GCTTACCTACCCAGAGGCAG
<i>p53 promoter 2-F</i>	AGCTGGCCAGACCTATGCTT
<i>p53 promoter 2-R</i>	TCAGCGCTTCCAAGCGCTGA
<i>p53 promoter 3-F</i>	GCTGTAGTTCCAAGCGCTGA
<i>p53 promoter 3-R</i>	CCCCTAGTGAGTTGAGTCCTCG
<i>p53 promoter 4-F</i>	CTTCTTCTGCAGGAAGGCTTGT
<i>p53 promoter 4-R</i>	ATCTCCGCTGTGCTTCCTCT
<i>p53 promoter 5-F</i>	CAGCAGTCCGGAGCTAACG
<i>p53 promoter 5-R</i>	ACCTTTCACGTCCCCGGCT
<i>p53 promoter 6-F</i>	GCATCCCGATCAGATTTCGC
<i>p53 promoter 6-R</i>	TCAGTGCTGGTAGCAAGTAAGA
<i>p53 promoter 7-F</i>	GCTTCAGACCTGTCTCCCTCA
<i>p53 promoter 7-R</i>	TGCTCTCAGCTGGATCCTTCT
<i>p53 promoter 8-F</i>	GGGTGTGATATTACGAAAGCCT
<i>p53 promoter 8-R</i>	AGCTGGACAGTCGCCATGA
<i>p53 promoter 9-F</i>	CTCCCCAACTCCATTCCCTTGCTTC
<i>p53 promoter 9-R</i>	CTAGACTTTGAGAAGCTAAAACCTTTAGCGCC